123 related articles for article (PubMed ID: 23097067)
1. Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.
Cooper TJ; Guazzi M; Al-Mohammad A; Amir O; Bengal T; Cleland JG; Dickstein K
Eur J Heart Fail; 2013 Jan; 15(1):119-22. PubMed ID: 23097067
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
Guazzi M; Vicenzi M; Arena R
Eur J Heart Fail; 2012 Jan; 14(1):82-90. PubMed ID: 22067410
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy.
Tay EL; Papaphylactou M; Diller GP; Alonso-Gonzalez R; Inuzuka R; Giannakoulas G; Harries C; Wort SJ; Swan L; Dimopoulos K; Gatzoulis MA
Int J Cardiol; 2011 Jun; 149(3):372-6. PubMed ID: 20304507
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic and clinical benefits associated with chronic sildenafil therapy in advanced heart failure: experience of the Montréal Heart Institute.
Potter BJ; White M; Carrier M; Pellerin M; L'Allier PL; Pelletier GB; Racine N; Ducharme A
Can J Cardiol; 2012; 28(1):69-73. PubMed ID: 22129489
[TBL] [Abstract][Full Text] [Related]
6. Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?
Amin A; Mahmoudi E; Navid H; Chitsazan M
Congest Heart Fail; 2013; 19(2):99-103. PubMed ID: 23241003
[TBL] [Abstract][Full Text] [Related]
7. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
Behling A; Rohde LE; Colombo FC; Goldraich LA; Stein R; Clausell N
J Card Fail; 2008 Apr; 14(3):189-97. PubMed ID: 18381181
[TBL] [Abstract][Full Text] [Related]
8. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
Garg N; Sharma MK; Sinha N
Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?
Waxman AB
Circulation; 2011 Jul; 124(2):133-5. PubMed ID: 21747065
[No Abstract] [Full Text] [Related]
11. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial.
Webster LJ; Michelakis ED; Davis T; Archer SL
Arch Intern Med; 2004 Mar; 164(5):514-20. PubMed ID: 15006828
[TBL] [Abstract][Full Text] [Related]
12. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.
Cooper TJ; Cleland JGF; Guazzi M; Pellicori P; Ben Gal T; Amir O; Al-Mohammad A; Clark AL; McConnachie A; Steine K; Dickstein K
Eur J Heart Fail; 2022 Jul; 24(7):1239-1248. PubMed ID: 35596935
[TBL] [Abstract][Full Text] [Related]
13. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
Guazzi M; Vicenzi M; Arena R; Guazzi MD
Circ Heart Fail; 2011 Jan; 4(1):8-17. PubMed ID: 21036891
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.
Iversen K; Jensen AS; Jensen TV; Vejlstrup NG; Søndergaard L
Eur Heart J; 2010 May; 31(9):1124-31. PubMed ID: 20202971
[TBL] [Abstract][Full Text] [Related]
15. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
Guazzi M; Vicenzi M; Arena R; Guazzi MD
Circulation; 2011 Jul; 124(2):164-74. PubMed ID: 21709061
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
Singh TP; Rohit M; Grover A; Malhotra S; Vijayvergiya R
Am Heart J; 2006 Apr; 151(4):851.e1-5. PubMed ID: 16569546
[TBL] [Abstract][Full Text] [Related]
18. PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials.
Zhuang XD; Long M; Li F; Hu X; Liao XX; Du ZM
Int J Cardiol; 2014 Apr; 172(3):581-7. PubMed ID: 24534379
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience.
Ruiz MJ; Escribano P; Delgado JF; Jiménez C; Tello R; Gómez MA; de la Calzada CS
J Heart Lung Transplant; 2006 Nov; 25(11):1353-7. PubMed ID: 17097500
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
